ERBB2 and neoplasm: Hence, it is yet unknown whether to select patients for HER2 targeting therapy by determining the HER2 status on either the primary (pre-neoadjuvant treatment) tumor, the (post-neoadjuvant treatment) resection specimen, or a metachronous recurrent site.